▲ DOT Compliance Update

Marijuana Is Still a Positive: What the DEA Rescheduling Means for DOT Drug Tests

The DEA just moved marijuana from Schedule I to Schedule III — but if you manage DOT-regulated employees, nothing has changed on the drug test front. A positive is still a positive, and a state medical card still isn’t a get-out-of-jail-free card.

The DEA Rescheduling: What Actually Changed

In a significant move under the Controlled Substances Act (CSA), the Drug Enforcement Administration issued an order reclassifying FDA-approved drug products derived from marijuana — and marijuana products regulated under a State medical marijuana license — from Schedule I to Schedule III.

For many industries, this is a meaningful regulatory shift. For employers and employees operating under DOT’s Part 40 drug testing framework, the practical impact on a positive lab result is exactly zero.

Official Guidance Source

This Q&A constitutes official guidance and interpretation from the Office of Drug and Alcohol Policy and Compliance and the Office of the General Counsel of the U.S. Department of Transportation concerning 49 CFR Part 40 — dated May 2026.

The Core Ruling: MROs Cannot Verify Marijuana Positives as “Negative.”

Official DOT Answer — 49 CFR §§ 40.137, 40.141, 40.151

Can a Medical Review Officer (MRO) deem a lab-confirmed marijuana positive as “negative” if the employee claims it came from a state-licensed marijuana product?

No. There is currently no instance in which an MRO can verify a laboratory-confirmed marijuana positive as “negative” when an employee claims the positive was caused by a state-licensed marijuana product.

This applies even after rescheduling. State-dispensed marijuana does not constitute an FDA-approved drug. Without FDA approval, it cannot be lawfully prescribed — full stop.

Why State Medical Marijuana Still Doesn’t Qualify

The standard for overturning a confirmed positive under Part 40 is a“legitimate medical explanation”— a legally prescribed controlled substance used in compliance with all Federal laws governing that prescription.49 CFR §§ 40.137(a); 40.141(b).

State marijuana programs operate entirely outside that framework. Here’s what the DOT says MROs may see from employees — and why none of it meets the Part 40 threshold:

• ✕ State-issued medical marijuana cards— do not satisfy Part 40’s “legitimate medical explanation” requirement

• ✕ Physician recommendations or certifications— not the same as a federally valid prescription for an FDA-approved drug

• ✕ Dispensary records or receipts— document a State-level transaction, not a federally lawful one

• ✕ Any non-prescription marijuana source— recreational or medical, state-licensed or otherwise

⚠️

Key takeaway:Marijuana use under State marijuana programs does not qualify as a “legitimate medical explanation” under49 CFR § 40.137(a). In addition, the DOT affirms thatmarijuana use is not compatible with safety-sensitive functions.

The FDA Approval Gap: Why Rescheduling Isn’t Enough

Here is the crux of the issue:rescheduling to Schedule III does not equal FDA approval. The DEA’s order changed marijuana’s scheduling classification, but FDA approval is a separate, rigorous process — one that marijuana products regulated by State medical programs have not gone through.

Under federal law, a controlled substance can only be legally prescribed when it has received FDA approval. Without that approval, there is no valid federal prescription pathway. Without a valid federal prescription, there is no “legitimate medical explanation” as defined by Part 40.

State-dispensed marijuana does not constitute an FDA-approved drug. Without FDA approval, it cannot be prescribed.

Until a marijuana-derived product completes the FDA drug approval process — a lengthy clinical trial and review pathway — DOT-regulated employers and their MROs are bound by the current federal standard. The rescheduling decision, while significant in other contexts, does not bridge that gap.

Safety-Sensitive Functions: Non-Negotiable

DOT’s drug testing program exists to protect the safety of the American public. Employees in safety-sensitive positions — commercial truck drivers, airline pilots, transit operators, pipeline workers, railroad employees, and others — are subject to these rules precisely because the stakes of impairment are extraordinarily high.

The DOT is explicit:marijuana use is not compatible with safety-sensitive functions. This is not a policy preference — it is a federal safety mandate, and it stands regardless of state law, cultural shifts around cannabis, or rescheduling actions.

Employer Action Item

Review your Employee Handbook, Reasonable Suspicion training materials, and MRO communication protocols to ensure they reflect current DOT guidance. Employees who inform you they hold a state medical marijuana card should be clearly counseled on the DOT’s position before a positive result creates a compliance crisis.

What DOT-Regulated Employers Should Do Right Now

• ✓ Brief your MRO on the official DOT guidance dated May 2026 to ensure consistent review practices

• ✓ Update supervisor training— supervisors may be fielding questions from employees who assume rescheduling changes their rights

• ✓ Communicate clearly with employees in safety-sensitive roles that state marijuana programs do not create an exception to DOT drug testing rules

• ✓ Do not accept state medical marijuana documentation as a basis for altering a verified positive result

• ✓ Consult your legal counsel if you receive pressure from employees or attorneys citing rescheduling as grounds to overturn a positive result

The Bottom Line

The DEA’s marijuana rescheduling is a headline-grabbing development — and in many legal and medical contexts, it matters. But in the DOT Part 40 drug testing world, the answer to the core question is unchanged:

Bottom Line for MROs & Employers

A lab-confirmed marijuana positive is a positive. A state medical card is not a prescription. A dispensary receipt is not a legitimate medical explanation.

The regulatory bar under 49 CFR Part 40 requires an FDA-approved drug and a federally lawful prescription. State marijuana programs satisfy neither requirement. Until that changes — and right now, it has not — MROs must verify these results are consistent with existing DOT rules.

Source: U.S. Department of Transportation, Office of Drug and Alcohol Policy and Compliance & Office of the General Counsel.Part 40 Questions and Answers — 49 CFR §§ 40.137, 40.141, 40.151. Dated 05/26. This Q&A constitutes official guidance and interpretation concerning 49 CFR Part 40 (see 49 CFR 40.5). These FAQs do not have the force and effect of law and are not meant to bind the public in any way. Compliance may be achieved in more than one way. Consult qualified legal counsel for advice specific to your situation.